P3 Health Partners(US:PIII) ZACKSยท2025-04-16 11:55Company Overview - P3 Health Partners Inc. (PIII) shares increased by 8.9% to close at $9.79, supported by high trading volume, contrasting with a 5% gain over the past four weeks [1] - The company reported fourth quarter revenue of $371 million, marking a 7% year-over-year increase, and reaffirmed its 2025 revenue guidance of $1.35 billion to $1.5 billion, with expectations of achieving profitability this year [2] Earnings Expectations - The upcoming report for P3 Health Partners is expected to show a quarterly loss of $5 per share, reflecting a year-over-year change of -3025%, with revenues anticipated at $363.75 million, down 6.4% from the previous year [3] - The consensus EPS estimate for the quarter has been revised 14.3% lower over the last 30 days, indicating a negative trend in earnings estimate revisions, which typically does not lead to price appreciation [4] Industry Context - P3 Health Partners operates within the Zacks Medical Info Systems industry, where another company, Pulmonx Corporation (LUNG), experienced a 9.1% decline in its stock price, closing at $4.92, and has returned -30.6% over the past month [4] - Pulmonx's consensus EPS estimate for the upcoming report remains unchanged at -$0.37, representing a -2.8% change from the previous year, and it currently holds a Zacks Rank of 3 (Hold) [5]